Pfiz­er racks up its third can­cer drug OK in 2 months, but is it enough to re­place reg­u­lar price hikes?

Pfiz­er has notched an­oth­er win for the late-stage drug pipeline, scor­ing an ac­cel­er­at­ed FDA ap­proval for lor­la­tinib, now head­ed for the mar­ket as Lor­bre­na.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER